Annual report [Section 13 and 15(d), not S-K Item 405]

Note 11 - Related party transactions (Details Textual)

v3.25.1
Note 11 - Related party transactions (Details Textual) - USD ($)
 12 Months Ended 38 Months Ended
Sep. 02, 2024
Aug. 27, 2024
Nov. 04, 2021
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Schedule of Equity Method Investments [Line Items]            
Loan payable to related party       $ 10,018,000   $ 10,018,000
Accrued liabilities       2,773,000 $ 8,829,000 2,773,000
Accounts payable       1,258,000 3,492,000 1,258,000
Related Party [Member]            
Schedule of Equity Method Investments [Line Items]            
Interest expense, related party       207,000    
Accrued interest on the unpaid principal loan       18,000   18,000
Loan payable to related party       10,000,000   10,000,000
Tuspetinib Licensing Agreement [Member]            
Schedule of Equity Method Investments [Line Items]            
License Fee, Total     $ 12,500,000      
Payments for License Fee     5,000,000      
Stock Issued During Period, Value, Licensing Fee     $ 7,500,000      
Supply Agreement [Member]            
Schedule of Equity Method Investments [Line Items]            
Expenses       $ 0 3,600,000 $ 7,100,000
Hanmi Loan Agreement [Member]            
Schedule of Equity Method Investments [Line Items]            
Loan is repayable date   Jan. 31, 2027        
Loan interest rate       6.00%   6.00%
Interest on loan paid       $ 189,000    
Convertible debt conversion $ 10,000,000          
Loan agreement amount   $ 10,000,000        
Hanmi Pharmaceuticals Co Ltd [Member]            
Schedule of Equity Method Investments [Line Items]            
Number of common shares held     7,190 99,647   99,647
Future milestone payments     $ 407,500,000      
Payment of supply costs       $ 2,600,000 4,500,000  
Warrants to purchase common shares, number of warrants       77,972   77,972
Common share exchange price       $ 51.3   $ 51.3
Hanmi Pharmaceuticals Co Ltd [Member] | Supply Agreement [Member]            
Schedule of Equity Method Investments [Line Items]            
Payment of supply costs       $ 2,600,000    
Reduced the accounts payable       0    
Accrued liabilities       0 0 $ 0
Accounts payable       $ 0 $ 2,600,000 $ 0